tbuckley/cabot-search huggingface dataset:
AB0406 Cardiovascular risk in rheumatoid arthritis: Are we aware?:
Authors: M. Valls Roc, S. Darnes, O. Codina, M. Sala
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> patients with rheumatoid arthritis (RA) have a higher cardiovascular (CV) morbidity and mortality from accelerated atherosclerosis than the general population. The increased risk appears because of an increased prevalence of clasic CV risk factors (age, male gender, smoking, diabetes, obesity, hypertension, elevated total cholesterol and low HDL) and the inflammatory burden. Early and effective antirheumatic treatment, such as methotrexate and tumor necrosis factor-α blocking agents has been shown to be independently associated with lower CV risk. <i>EULAR</i> evidence-based recommendations for <i>cardiovascular risk</i> management published in 2009 advised determine CV risk assessment using national guidelines for all patients with RA. <h3>Objectives</h3> determine CV risk in RA patients monitored in the Rheumatology section of county hospital. The reference area had a population of 130.000 inhabitants. Asses the relationship between the degree of RA activity and CV risk. Analyze the correlation between the drugs used to treat RA and CV risk. <h3>Methods</h3> observational retrospective cohort pilot study. Patients had been recruited in rheumatology outpatient clinic. All patients fulfilled the 1987 RA criteria of the American College of Rheumatology. The aim is to determine the CV risk in patients with RA according to Framingham-REGICOR (F-REGICOR) and SCORE tables for european countries with low CV risk. Data was collected between January to June 2011 and included: age, sex, smoking, blood pressure (BP), total cholesterol and HDL, disease activity by DAS28 and drugs administered. <h3>Results</h3> of 298 RA patients monitored in our center, only 38 (12.8%) had recorded enough variables to calculate CV risk. 17 men and 21 women, mean age 57.8±11.1 years. 7 patients smokers, 18.4% of the total. Mean systolic BP was 137.5 mmHg and diastolic BPof 76.9 mmHg. Mean total cholesterol was 208.4 mg/dl and HDL cholesterol of 53 mg/dl. Results of CV risk determinations according to F-REGICOR and SCORE are shown in table below. DAS28 had an average of 2.9 with SD 1.1. Linear regression analysis ruled out a significant association between DAS28 and CV risk. The drugs used by patients were: 58% NSAID, 60% corticosteroids, 63% methotrexate, 18% leflunomide and 32% biologics. There was no statistically significant differences between the different drug groups and each group of cardiovascular risk. <h3>Conclusions</h3> we were able to determine CV risk in 12.8% of RA patients. Half of patients have low CV risk. Not found a significant association between cardiovascular risk and RA activity neither in relation to the drugs used. <h3>Disclosure of Interest</h3> None Declared
Unsuspected Perforated Richter Hernia in the Inguinal Canal Detected by F-18 FDG PET/CT
Authors: Aaron M. Betts, Kevin P. Banks, Agnieszka O. Solberg
Journal: Clinical Nuclear Medicine (2011)

An 86-year-old man presented with fatigue and weight loss. Combined F-18 fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET/CT) demonstrated a heterogeneous soft-tissue mass continuous with the small bowel in the left inguinal region, with marked hypermetabolic activity on PET images. Physical examination of the left groin demonstrated a previously unidentified nonreducible, tender mass. Surgical exploration revealed a perforated Richter hernia in the internal inguinal ring with adjacent groin abscess. Pathologic evaluation confirmed these findings without underlying malignancy.
Resolving Ambiguity in Emotional Disorders: The Nature and Role of Interpretation Biases
Authors: Colette R. Hirsch, Frances Meeten, Charlotte Krahé, Clare Reeder
Journal: Annual Review of Clinical Psychology (2016)

People with emotional disorders, such as social anxiety disorder (SAD), generalized anxiety disorder (GAD), and depression, demonstrate a consistent tendency, or bias, to generate negative interpretations of ambiguous material. This is different from people without emotional disorders who tend, in general, to make positive interpretations of ambiguity. If central components of an emotional disorder have high levels of inherent ambiguity (e.g., concern about the negative perceptions of others in SAD, or worry in GAD), then interpretive bias may have a causal maintaining role, and this has been demonstrated in studies using cognitive bias modification techniques. This research has also shown that interpretation biases combine with other cognitive processes, such as imagery and memory, which could exacerbate distress. Psychological interventions will benefit from effectively targeting negative interpretations, and future experimental research can inform ways to improve facilitation of more benign inferential processing to maximize amelioration of key components of emotional disorders.
PREDICTION OF CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY WITH ERECTILE DYSFUNCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF COHORT STUDIES
Authors: Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, Nikolaos Ioakeimidis, Konstantinos Aznaouridis, Konstantinos Rokkas, Alexandros Synodinos, Evaggelia Christoforatou, Athanasios Aggelis, Alexios Samentzas, Christodoulos Stefanadis
Journal: Journal of the American College of Cardiology (2012)
Spread the experience of India in China: making endoscopy mobile
Authors: X.-W. Tang, S. Huang, Z.-N. Fan
Journal: Endoscopy (2012)

We read with great interest the article by Talukdar & Reddy, "Making endoscopy mobile: a novel initiative for public healthcare" [1]. The authors introduced their experience of delivering mobile endoscopy in remote rural areas in India. They converted a bus into a mobile hospital equipped with custom-made diagnostic and therapeutic endoscopy equipment, and traveled to remote rural regions to provide diagnostic and other quality healthcare services to underserved rural populations. Over the past 5 years this initiative, the Rural Health Care Project, has benefited nearly 10 million patients in southern India. In addition to providing high quality healthcare to these underserved rural regions, the authors have recorded valuable epidemiological data on gastrointestinal diseases within these regions and trained young physicians who could continue to provide these services. This project proved to be a cost-effective healthcare service.
Abstract 522: Comparison of ovarian cancer spheroids and three-dimensional cell movement with the spheroids formed by normal ovarian surface epithelial and fallopian tube epithelial cells using an <i>in vitro</i> culture system
Authors: Pui-Wah Choi, Hanna Megan, Wing-Ping Fong, Shu-Wing Ng
Journal: Cancer Research (2010)

Abstract Ovarian cancer is the most lethal cause of death among gynecological cancers. Recent studies have suggested that the cells of origin of ovarian cancer might be the ovarian surface epithelial (OSE) cells and epithelial cells derived from other Mullerian ducts such as distal fallopian tube. It is believed that these cells exist as cortical inclusion cysts in the ovary, to which the extracellular matrix (ECM) proteins, proteases, secreted growth factors and chemokines from the stromal microenvironment can provide oncogenic signals in a paracrine fashion. In order to investigate the molecular mechanisms and signaling events governing these processes, we grew ovarian cancer cell lines, normal OSE and fallopian tube epithelial (FTE) primary cells as three-dimensional (3D) cultures in Matrigel, which was enriched with basement membrane proteins. Most of the cells formed spheroid structures resembling ovarian inclusion cysts, with sizes ranging from 50 to 100 μm. One cancer cell line formed spindle-like structure. The multicellular structures were stained for membrane markers and examined using confocal laser scanning microscopy. Most of the cancer spheroids were consisted of tightly packed polarized epithelial cells, as revealed by lateral β-catenin and E-cadherin staining, and GM130 staining at the apical surface outlining a central lumen. In contrast, normal OSE spheroids and FTE spheroids showed less organized structure with random β-catenin and GM130 staining. To evaluate the growth and progression of the cancer cells in response to stimuli from a stromal microenvironment, the spheroids were transferred to a collagen matrix. Interestingly, the majority of the cancer cells migrated out of the spheroids in a collective movement similar to the lymphatic metastasis observed in breast cancer. The morphology of the collectively moving cells was distinctively different from that expected from an epithelial-mesenchymal transition model. Ongoing gene expression profiling and characterization of the cells growing in the 3D spheroids will reveal the molecular mechanisms underlying the morphogenic changes and may provide insights into the growth and progression of clinical ovarian cancer from inclusion cysts. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 522.
PMO-096 Laparoscopic distal pancreatectomy—a tertiary referral centre experience
Authors: A Morhan, P Griffiths, T Brown, B Al-Sarireh
Journal: Gut (2012)

<h3>Introduction</h3> Laparoscopic distal pancreatectomy was first reported in 1996 and is increasingly employed to remove lesions from the body and tail of the pancreas. The technique has seen a slow progress due to a relatively low volume of caseload, the lack of standardisation in the management of the pancreatic stump and concerns about the ability to achieve negative surgical margins for benign or malignant pancreatic neoplasms. <h3>Methods</h3> Data were collected by retrospective review of case notes and histopathological results. 20 patients underwent laparoscopic distal pancreatectomy from April 2009 to January 2012. <h3>Results</h3> 20 patients were included in the study, 0.45:1 male: female ratio (nine males, 20 females), mean age 58.55 [range 25–83]. In most cases the indication for surgery was a cystic lesion in the tail of pancreas (45%). The spleen was preserved in 15 cases (75%). None of the patients in this series required conversion from laparoscopic to open surgery or blood transfusion. Four patients (20%) were transferred to HDU postoperatively for 1–5 days and the mean hospital stay was 8.5 days [range 3–23 days]. Four patients (20%) had postoperative complications: one had partial splenic infarction which was managed conservatively, one had fluid collection that was treated by percutaneous drainage, one had a pancreatic stump leak that settled conservatively and one had abscess which required surgical intervention. The latter had laparoscopic right hemicolectomy at the same time of his pancreatic resection. There was no indication of a pancreatic fistula at follow-up. Histology confirmed one chronic abscess, one congenital cyst, five cancers, six potentially malignant lesions and seven serous microcystic cystadenomas. All tumours were completely excised with clear resection margins. <h3>Conclusion</h3> Laparoscopic resection is feasible and achieves adequate resection margins. <h3>Competing interests</h3> None declared. <h3>References</h3> 1. <b>Pierce RA</b>, <i>et al.</i> Outcomes analysis of laparoscopic resection of pancreatic neoplasms. <i>Surg Endosc</i> 2007;<b>21</b>:579–86. 2. <b>Abu Hilal M</b>, <i>et al.</i> Laparoscopic distal pancreatectomy: critical analysis of preliminary experience from a tertiary referral centre. <i>Surg Endosc</i> 2009;<b>23</b>:2743–7. 3. <b>Mahon D</b>, <i>et al.</i> Laparoscopic distal pancreatectomy. Three cases of insulinoma. <i>Surg Endosc</i> 2002;<b>16</b>:700–2.
Where is the EHR in Oncology?
Authors: Jeremy Warner, Ephraim Hochberg
Journal: Journal of the National Comprehensive Cancer Network (2012)

Electronic health records (EHRs) have the potential to increase the quality and decrease the cost of cancer care. These twin goals can only be met by a fully functional oncology EHR, which includes at a minimum: searchable data repositories, clinical decision support (CDS), the ability to electronically order chemotherapeutic medications, and the ability to interface with patients via a patient portal. Such fully functional EHRs not only offer patients the best potential for high-quality care, they enable retrospective analysis to answer a wide variety of comparative effectiveness and quality improvement questions. The significant barriers of cost, time pressures, aversion to CDS, and interoperability will need to be overcome if EHRs are to be meaningfully used by the majority of oncologists.
AB1063 The use of glucocorticosteroids does not dismiss the lumbar bone mineral density in patients with rheumatoid arthritis, prospective study
Authors: J. Del Pino, R. Pedrero, R. Lopez-Gonzalez, C. Montilla-Morales, S. Gomez-Castro, M.D. Sanchez-Gonzalez, C. Hidalgo-Calleja, P. García-Talavera
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The increase of pro-inflammatory cytoquines plays a relevant role in the loss of bone density which is associated to the Rheumatoid Arthritis (RA). The glucocorticosteroids (GC) are in the base of the treatment and have been described as a losing body mass index (BMI) risk factor, even a small continuing dosage, based in that suggestion it is consider the use of GC in RA patients a combination of risk factor of fracture, which it is reflected in the absolute risk calculator as the FRAX index. There are studies which have compared the use of GC in patients related with healthy control, but there are not studies which related the effect at the BMI of the GC prescription in RA patients. <h3>Objectives</h3> To estimate the BMI variation in RA patients treated with GC <h3>Methods</h3> Longitudinal study of 69 women with RA, during 5 years. Socio-demographic, clinical and BMI characteristics were recorded, which was measure with dual-emission X-ray absorptiometry technique in two levels total lumbar spine and femoral neck. Descriptive analyses were performed, and was described the predictors of decreased of the BMI in patients treated with GC and/or bisfosfonates (BPS) drugs, a value p&lt;0,05 was consider statistical significance. <h3>Results</h3> 100% were women with a mean age of 59.9 years ± 11 years, 13% premenopausal. Related to the drugs: 1) The use of GC was up to 58.2% of the patients, with a mean accumulated dosage of 4.5 grams during a mean time of 2.8 years; only 7.2% received high dosage of GC; 2) Up to 43.5% of the patients had a BPS prescription. Related to the RA: the mean duration was 9.8 years; the HAQ index mean was 1.25 and the mean of the illness activity assessing with the DAS-28 was 3.43. It was calculated the BMI evolution depending of the basal treatment, GC or/and BPS. It was observed a better BMI improvement in the group of RA patients treated with GC with a p=0.024; it was also an improvement of p=0.001 in the group treated with BPS. The difference between the mean of the group without GC and without BPS -0.024 (p=0.048) and the group with GC and without BPS 0.027 (p=0.0467). <h3>Conclusions</h3> The effects of the GC over the pro-inflammatory cytokines of the bone prescribed to get a better control of the RA activity, let to control the effects of the bone loss due to the inflammatory illness, RA. This work shows how the use of GC in the RA patients must not be consider as an aggravated risk factor to the osteoporosis associated to the RA. <h3>Disclosure of Interest</h3> None Declared
Abstract 2832: Genetic variation in <i>TGFB1</i>, <i>TGFBR1</i>, <i>TGFBR2</i>, and prostate cancer risk and recurrence
Authors: Iona C. Cheng, Sarah Plummer, Joel Mefford, Christine Neslund-Dudas, Graham Casey, Benjamin Rybicki, John Witte
Journal: Cancer Research (2010)

Abstract Background: The transforming growth factor-β (TGF-β) signaling pathway has been reported to play a dual role in prostate carcinogenesis. Initially, TGF-β signaling inhibits tumor growth by its antiproliferative activity, but eventually it promotes tumor development by enhancing tumor cell motility and metastasis. We investigated whether common genetic variation in TGFB1, TGFBR1, and TGFBR2 influences the risk of aggressive prostate cancer and biochemical recurrence. Methods: Forty-four tag SNPs in TGFB1, TGFBR1, and TGFBR2 were examined in a case-control study of aggressive prostate cancer (501 cases/538 controls) and a follow-up study of biochemical recurrence (824 cases). Aggressive disease was defined as having either having a Gleason score ≥7 or TNM stage ≥ T2c, or PSA at diagnosis &amp;gt;10 ng/ml. Biochemical recurrence was defined as post-treatment prostate specific antigen (PSA) levels &amp;gt;0.3 ng/ml for radical prostatectomy patients or 2 ng/ml increase above the nadir for radiotherpay patients. Odds ratios (OR) and 95% Confidence Intervals (CI) were estimated by unconditional logistic regression to evaluate the association between SNPs and aggressive prostate cancer risk. Hazard ratios (HR) and 95% CI were estimated by Cox proportional hazard regression to examine the association between SNPs and biochemical recurrence. Results: For risk of aggressive disease, three SNPs were nominally statistically significant (TGFB1-rs4803455; TGFBR1-rs10512263; TGFBR2-rs2276768) with the most compelling polymorphism (TGFBR1-rs10512263) having an OR=1.76; 95% CI: 1.14-2.43 (P = 0.008) per additional minor allele. For risk of biochemical recurrence, seven SNPs were nominally statistical significant (TGFBR1- rs10739778; TGFBR2- rs12493607, rs2082224, rs1346907, rs1431131, rs1835538, rs11129421) with TGFBR2- rs12493607 associated with a HR=1.40; 95% CI: 1.14-1.71; P=0.001 per additional minor allele. Conclusion: Our study suggests that genetic variation in the TGF-β pathway may be associated with risk of aggressive prostate cancer and biochemical recurrence. Future work will evaluate the cumulative and interactive effects of the associations within this pathway on prostate cancer risk and recurrence. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2832.
Addition of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) to Trastuzumab Stabilizes Disease in Patients with Trastuzumab-Resistant, HER2+ Metastatic Breast Cancer.
Authors: Y. Cheng, Y. Cheng, V. Valero, M. Davis, G. Hortobagyi, N. Ueno, N. Ueno
Journal: Cancer Research (2009)

Abstract Introduction: Trastuzumab with or without chemotherapy is the standard of care for patients with HER2+ metastatic breast cancer. The proposed mechanism of trastuzumab-induced regression of HER2+ tumors includes inhibition of tumor cell proliferation, potentiation of chemotherapy, and facilitation of immune function through antibody-dependent cell-mediated cytotoxicity. GM-CSF (Leukine) is a cytokine that mediates antibody-dependent cell-mediated cytotoxicity. We studied the feasibility and efficacy of adding GM-CSF to trastuzumab in patients with trastuzumab-resistant, HER2+ metastatic breast cancer.Patients and Methods: Patients with measurable, HER2+ metastatic breast cancer that progressed after treatment with trastuzumab with or without chemotherapy were continued on trastuzumab alone at 2 mg/kg intravenous weekly. GM-CSF (250 μg/m2 subcutaneous daily) was added until the absolute neutrophil count (ANC) was greater than 10,000/mm3, then given every other day while the ANC was maintained below 10,000/mm3. Disease was restaged every 8 weeks. Treatment with trastuzumab and GM-CSF was continued until disease progression or intolerable toxicity.Results: Of 18 eligible patients with progressive HER2+ metastatic breast cancer, 17 (median age 48 yr, range 27–75 yr) were evaluable. Nine had hormone receptor–positive disease. The median number of metastatic sites was 2 (range 1–3); the most common site was the liver (n=10). The median number of prior regimens (trastuzumab with or without chemotherapy) for metastatic disease was 2 (range 1–5). One patient developed rapidly progressive disease 2 weeks after the start of study therapy and died soon after. The other 16 patients continued treatment until disease progression. No disease response was observed, but 5 patients (29%) had stable disease with a median duration of 15.8 weeks (range 10–53.9 weeks). Thirteen patients had grade 1 toxic effects; 6 patients, grade 2; and 2 patients, grade 3 (fatigue and muscle aches). The most common toxic effect was rash at the injection site, followed by skin rash, fatigue, and muscle aches. No grade 4 or irreversible toxic effect was seen.Conclusion: The addition of GM-CSF to trastuzumab alone in patients with trastuzumab-resistant, HER2+ metastatic breast cancer stabilizes the disease for a median duration of 15.8 weeks without causing any significant toxic effects in 29% of heavily pretreated patients. Its administration is simple, safe, and feasible. This regimen, trastuzumab and GM-CSF, needs further evaluation in combination with chemotherapy or other biological agents. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5103.
Abstract 245: An oncogenic role for <i>CCAAT/enhancer binding protein beta</i> in non-small cell lung cancer
Authors: Nils H. Thoennissen, Gabriela B. Iwanski, Jianfei Ji, Takayuki Ikezoe, Kunik Lee, Yoshihiro Adachi, Tamotsu Takeuchi, Mutsuo Furihata, Dorothy J. Park, Adrian F. Gombart, H. Phillip Koeffler
Journal: Cancer Research (2010)

Abstract The transcription factor CCAAT/enhancer binding protein (C/EBP) beta is known to be a mediator of cellular transformation and tumorigenesis in human colon, breast and ovary cancer. In this study, we focused on C/EBPbeta and its potential role in non-small cell lung cancer (NSCLC). Immunohistochemical staining of 60 human NSCLC samples (adeno- (31), squamous cell - (25), small cell - (1), large cell - (2), and adeno-squamous cell (1) carcinoma) showed that more than 50% of the tumor samples were significantly positive for nuclear staining of C/EBPbeta compared to healthy airway epithelial cells. Retrovirus-delivered siRNA knock-down of C/EBPbeta expression in human NSCLC cell lines A549, H520, and H460 markedly reduced clonogenic growth, which was accompanied by a significant reduction in cyclooxygenase(COX)-2 expression, increase in G0/G1 cells, and PARP cleavage activity. In contrast, using NSCLC cell line Calu-3 with a moderate intrinsic level of C/EBPbeta, forced expression of this transcription factor even increased clonogenic growth and cell proliferation. Whereas recent studies suggested that family member C/EBPalpha has growth-inhibitory properties in airway epithelial cells, our present data indicate an oncogenic role of C/EBPbeta in NSCLC and may represent a new target for cancer co-therapy to increase response to existing chemotherapeutic regimens. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 245.
IMPACT OF MORPHINE ON PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF TICAGRELOR IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Francesco Franchi, Fabiana Rollini, Jung Rae Cho, Mona Bhatti, Christopher DeGroat, Elisabetta Ferrante, Elizabeth C. Dunn, Amit Nanavati, Edward Carraway, Siva Suryadevara, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass, Dominick J. Angiolillo
Journal: Journal of the American College of Cardiology (2015)